Stock Scorecard
Stock Summary for Charles River Laboratories International Inc (CRL) - $174.76 as of 12/3/2025 3:46:06 PM EST
Total Score
4 out of 30
Safety Score
48 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for CRL
| Positive Quarterly and Annual earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the Annual earnings growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for CRL
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for CRL
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for CRL
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for CRL (48 out of 100)
| Stock Price Rating (Max of 10) | 10 |
| Historical Stock Price Rating (Max of 10) | 10 |
| Stock Price Trend (Max of 10) | 1 |
| Book Value (Max of 10) | 9 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 3 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 4 |
| Trading Volume (Max of 10) | 6 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for CRL
Financial Details for CRL
Company Overview |
|
|---|---|
| Ticker | CRL |
| Company Name | Charles River Laboratories International Inc |
| Country | USA |
| Description | Charles River Laboratories International, Inc. (CRL) is a leading global provider of critical products and services designed for the pharmaceutical, biotechnology, and medical device industries. The company excels in offering a complete range of preclinical and clinical laboratory services, alongside cutting-edge gene and cell therapy solutions that significantly bolster research and development efforts. With a strong emphasis on innovation and adherence to regulatory standards, Charles River plays a vital role in facilitating efficient drug development processes, thereby contributing to the advancement of healthcare solutions on a global scale. |
| Sector Name | HEALTHCARE |
| Industry Name | DIAGNOSTICS & RESEARCH |
| Most Recent Quarter | 9/30/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 174.76 |
| Price 4 Years Ago | 376.78 |
| Last Day Price Updated | 12/3/2025 3:46:06 PM EST |
| Last Day Volume | 636,420 |
| Average Daily Volume | 1,125,298 |
| 52-Week High | 202.72 |
| 52-Week Low | 91.86 |
| Last Price to 52 Week Low | 90.25% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 38.04 |
| Sector PE | 88.06 |
| 5-Year Average PE | 23.19 |
| Free Cash Flow Ratio | 41.41 |
| Industry Free Cash Flow Ratio | 70.75 |
| Sector Free Cash Flow Ratio | 28.78 |
| Current Ratio Most Recent Quarter | 1.37 |
| Total Cash Per Share | 4.22 |
| Book Value Per Share Most Recent Quarter | 69.19 |
| Price to Book Ratio | 2.55 |
| Industry Price to Book Ratio | 232.27 |
| Sector Price to Book Ratio | 33.12 |
| Price to Sales Ratio Twelve Trailing Months | 2.14 |
| Industry Price to Sales Ratio Twelve Trailing Months | 4.86 |
| Sector Price to Sales Ratio Twelve Trailing Months | 15.97 |
| Analyst Buy Ratings | 9 |
| Analyst Strong Buy Ratings | 1 |
Share Statistics |
|
| Total Shares Outstanding | 49,215,500 |
| Market Capitalization | 8,600,900,780 |
| Institutional Ownership | 106.74% |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 2.40% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | -17.30% |
| Annual Earnings Growth | -97.83% |
| Reported EPS 12 Trailing Months | -1.52 |
| Reported EPS Past Year | 7.89 |
| Reported EPS Prior Year | 10.32 |
| Net Income Twelve Trailing Months | -83,482,000 |
| Net Income Past Year | 10,297,000 |
| Net Income Prior Year | 474,624,000 |
| Quarterly Revenue Growth YOY | -0.50% |
| 5-Year Revenue Growth | 9.09% |
| Operating Margin Twelve Trailing Months | 15.80% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 207,670,000 |
| Total Cash Past Year | 194,606,000 |
| Total Cash Prior Year | 276,771,000 |
| Net Cash Position Most Recent Quarter | -1,977,783,000 |
| Net Cash Position Past Year | -2,045,599,000 |
| Long Term Debt Past Year | 2,240,205,000 |
| Long Term Debt Prior Year | 2,647,147,000 |
| Total Debt Most Recent Quarter | 2,185,453,000 |
| Equity to Debt Ratio Past Year | 0.61 |
| Equity to Debt Ratio Most Recent Quarter | 0.61 |
| Total Stockholder Equity Past Year | 3,461,503,000 |
| Total Stockholder Equity Prior Year | 3,596,882,000 |
| Total Stockholder Equity Most Recent Quarter | 3,405,449,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | 543,670,000 |
| Free Cash Flow Per Share Twelve Trailing Months | 11.05 |
| Free Cash Flow Past Year | 501,610,000 |
| Free Cash Flow Prior Year | 365,370,000 |
Options |
|
| Put/Call Ratio | 4.32 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 0.20 |
| MACD Signal | -1.03 |
| 20-Day Bollinger Lower Band | 144.09 |
| 20-Day Bollinger Middle Band | 167.65 |
| 20-Day Bollinger Upper Band | 191.21 |
| Beta | 1.64 |
| RSI | 57.23 |
| 50-Day SMA | 158.40 |
| 150-Day SMA | 193.89 |
| 200-Day SMA | 204.88 |
System |
|
| Modified | 12/3/2025 8:59:58 PM EST |